SPA
WST icon

Sherbrooke Park Advisers’s West Pharmaceutical WST Stock Holding History

Sherbrooke Park Advisers’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,919
Closed -$676K – 1007
2023
Q4 		$676K Buy
+1,919
New +$679K 0.32% 106
2023
Q3 		– Sell
-900
Closed -$344K – 628
2023
Q2 		$344K Buy
+900
New +$322K 0.18% 236

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Sherbrooke Park Advisers's WST Position: Q1 2024 in Review

Sherbrooke Park Advisers sold out of West Pharmaceutical (WST) in Q1 2024, closing a stake of 1,919 shares — an estimated $676K sold.

Sherbrooke Park Advisers first reported a position in WST in Q2 2023 and held it in 2 quarters. The position peaked at $676K in Q4 2023. 778 funds tracked by Wall St. Rank hold WST as of Q1 2024.

  • Sherbrooke Park Advisers reported no remaining West Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 1,919 West Pharmaceutical shares in Q1 2024, an estimated $676K.
  • Sherbrooke Park Advisers first reported a position in West Pharmaceutical in Q2 2023 and held it in 2 quarters.
  • Sherbrooke Park Advisers's West Pharmaceutical position peaked at $676K in Q4 2023.
  • 778 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2024, filed 15 May 2024.